Komori
Daito Pharmaceutical (4577) · RiskWorsened

Intellectual Property Risks Relating to Generic Drugs

First written in FY2016. 2 of 5 entries say "Restated". Latest entry: FY2026.

5entries
11years
0from disclosures
Share on X
How it moved
ProgressHeldSoftenedWorseRestatedFY2016 – FY2018MitigatedFY20202016: 12017: 120172018: 120182019: 020192020: 120202021: 020212022: 020222023: 020232024: 020242025: 020252026: 12026
Same theme, other companies
Risk of Infringing Third-Party Intellectual Property RightsA theme 465 companies write about · 468 as a headwind · 1 as a tailwind
Ridges = years it wrote progress, valleys = years it wrote worse. Most hopeful companies at the back. Drag to turn, scroll to zoom, right-drag to pan. On a phone, two fingers turn and pinch to zoom; one finger scrolls the page.
Showing 14 of the 197 companies compared. The sentences above are computed from all 197.Comparing 200 of the theme's 469 threads.
Full recordFilings, disclosures and news, newest first
  1. FY2026WorsenedAnnual report

    「The emergence of judicial decisions broadly recognizing the scope of protection afforded by originator drug manufacturers' patents, and the increasing difficulty of patent strategy」

    In addition to the existing risks of patent infringement and litigation, it identifies as industry issues the emergence of judicial decisions broadly recognizing the scope of protection afforded by originator drug manufacturers' patents and the increasing difficulty of patent strategy.
  2. FY2020MitigatedAnnual report

    「To address these risks, the Group not only complies with the various laws and regulations relevant to its business, but also works to prevent disputes by obtaining the cooperation of attorneys and other specialists, clarifying rights and obligations through appropriate contracts, and investigating the rights of third parties.」

    As measures addressing intellectual-property infringement and litigation risks, it specifically describes obtaining specialist assistance, clarifying rights and obligations through contracts, and investigating third-party rights.
  3. FY2018RestatedAnnual report

    「The Group may face litigation on the grounds of suspected patent infringement, and if such a situation arises, its business performance and other results may be affected.」

    Reiterates the risks of infringement and litigation involving patents, design rights and other rights relating to generic pharmaceuticals.
  4. FY2017RestatedAnnual report

    「The Group may face litigation on the grounds of suspected patent infringement, and if such a situation arises, its business performance and other results may be affected.」

    Reiterates the risks of infringement and litigation involving patents, design rights and other rights relating to generic pharmaceuticals.
  5. FY2016First statedAnnual report

    「The Group may face litigation on the grounds of suspected patent infringement, and if such a situation arises, its business performance and other results may be affected.」

    Explains that it investigates substance and use patents, crystal forms, manufacturing processes, formulations, design rights and other rights.
Moved together

"Risk of Fluctuations in Raw Material and Purchase Prices" moved the same way as this thread, in the same document, in 2 of its 5 moves.

2★1
  1. ★This thread
  2. 1Risk of Fluctuations in Raw Material and Purchase Prices2×

★ is this thread; numbers match the list above. The number on a line is how many documents both moved the same way in; lines between the other threads count the documents they moved together in too. Threads that move together often sit closer.

When this could move next
No upcoming earnings preview for Daito Pharmaceutical yet.
News
No news is linked to this thread yet. When an article touches it, it will appear here by date.
Intellectual Property Risks Relating to Generic Drugs | Daito Pharmaceutical Co.,Ltd. (4577) | Komori